Genetically engineered CSPG4-targeted chimeric antigen receptor T (CAR-T) cells were effective in killing CS cells in vitro, suggesting that CSPG4-targeted CAR-T cells could represent an effective strategy in the treatment of CSPG-4 expressing CS [98]. Here, CSPG4 is linked to Cowden syndrome 1.